| CORONA Remedies Limited announced its unaudited financial results for the first quarter of fiscal year 2027, reporting revenue of Rs 422.4 crore, a 21.9% year-over-year increase, and profit after tax of Rs 60.1 crore, a 30.1% year-over-year increase. The company, a leading India-focused branded pharmaceutical company, also inaugurated a European Union Good Manufacturing Practice (EU-GMP) approved Female Hormone Manufacturing Facility in Ahmedabad and initiated the integration of the acquired brand, Wokadine. |